WallStreetZenWallStreetZen

NASDAQ: AKTX
Akari Therapeutics PLC Stock Ownership - Who owns Akari Therapeutics?

Insider buying vs selling

Have Akari Therapeutics PLC insiders been buying or selling?
No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when AKTX insiders and whales buy or sell their stock.

AKTX Shareholders

What type of owners hold Akari Therapeutics PLC stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Rpc Pharma Ltd9.70%722,345,600$2.61BInsider
James Hill9.70%722,345,600$2.61BInsider
Stuart Ungar9.70%722,345,600$2.61BInsider
Ray Prudo9.70%722,345,600$2.61BInsider
Sabby Management LLC0.10%7,392,131$26.76MInstitution
Mark S. Cohen0.01%1,055,600$3.82MInsider
Omnia Family Wealth LLC0.01%782,372$2.83MInstitution
Sabby Management LLC0.01%778,030$2.82MInsider
Nea Management Company LLC0.01%452,167$1.64MInstitution
Cerity Partners LLC0.00%322,862$1.17MInstitution

1 of 3

AKTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AKTX0.14%38.84%
ENLV1.63%77.30%
EQ28.70%41.40%Net Buying
LMNL0.44%0.00%
EVGN1.69%0.00%

Akari Therapeutics Stock Ownership FAQ

Who owns Akari Therapeutics?

Akari Therapeutics (NASDAQ: AKTX) is owned by 0.14% institutional shareholders, 38.84% Akari Therapeutics insiders, and 61.03% retail investors. Rpc Pharma Ltd is the largest individual Akari Therapeutics shareholder, owning 722.35M shares representing 9.70% of the company. Rpc Pharma Ltd's Akari Therapeutics shares are currently valued at $2.61B.

If you're new to stock investing, here's how to buy Akari Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.